$FEMY Cashflow Statement | Understand Stock

$FEMY

$1.37 -$0.04 (2.84%) Close

$FEMY Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Amortization
Amortization of discount on investments
Other noncash items
Change in fair value of conversion option liability
Change in fair value of warrants liabilities
Amortization of right-of-use assets
Inventory reserve
Accounts receivable reserve
Loss on fixed asset dispositions
Share-based compensation expense
Loan and accrued interest forgiveness on note payable
Amortization of debt issuance costs and discount
Accretion of paid-in-kind interest

Changes in operating assets and liabilities:
Accounts receivable
Inventory
Prepaid and other assets
Accounts payable
Accrued expenses and other
Accrued expenses
Lease liabilities
Other liabilities
Net cash used in operating activities

Cash flows from investing activities:
Maturities of short-term investments
Acquisition of patents
Purchases of property and equipment
Net cash used in investing activities

Cash flows from financing activities:
Proceeds from the issuance of common stock and warrants in April 2023 Financing
Proceeds from the issuance of common stock
June 2025 Financing
August 2025 Financing
Total proceeds from the issuance of common stock
Proceeds from note payable
Payments of deferred offering costs
Issuance costs
June 2025 Financing
August 2025 Financing
Proceeds from exercise of pre-funded warrants
Proceeds from exercise of common warrants
Proceeds from November 2025 convertible notes
Issuance costs for November 2025 convertible notes
Proceeds from common stock issued through ESPP
Proceeds from at-the-market sales of common stock
Issuance costs for at-the-market sales of common stock
Repayment of November 2023 convertible notes, including related parties
Repayment of note payable
Payments under lease obligations
Net cash provided by financing activities
Net change in cash and cash equivalents

Cash and cash equivalents:
Beginning of period
End of period
Cash paid for:
Interest
Income taxes
Non-cash investing and financing activities:
Conversion of convertible preferred stock to common stock
Deferred offering costs included in accounts payable and accrued expenses
Right-of-use asset obtained in exchange for a lease liability
Commissions costs relating to certain proceeds from issuance of common stock
Prepaid insurance financed with promissory notes
Property and equipment costs included in accounts payable
Property and equipment costs included in accounts payable and accrued expense
Acquisition of patents included in accounts payable
Issuance of warrants for underwriter commission
June 2025 Financing
August 2025 Financing
Conversion of November 2023 convertible notes into common stock
Payment of November 2023 convertible note interest in common stock
Deferred offering costs reclassified to additional paid-in-capital
Fair value of conversion option liability at November 2025 issuance
Fair value of warrants liabilities at November 2025 issuance

Comments